Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04421339
Other study ID # HSC-MS-19-1111
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 22, 2021
Est. completion date September 16, 2022

Study information

Verified date May 2023
Source The University of Texas Health Science Center, Houston
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the efficacy of exogenous melatonin in improving sleep quality in HD gene carriers.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date September 16, 2022
Est. primary completion date September 16, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Verified HD mutation carriers. - Patients who report sleep disturbance as measured by a score =5 on the Pittsburgh Sleep Quality Index (PSQI); - Stable concomitant medication (no change of medication during last 30 days prior to inclusion); - Written informed consent by prospective study participant before conduct of any trial-related procedure; - Participant must be able to make an informed decision of whether or not to participate in the study. Exclusion Criteria: - Pregnant or nursing women; - Woman of childbearing potential, not using highly effective methods of contraception such as oral, topical or injected contraception, intrauterine device (IUD), contraceptive vaginal ring, or double barrier method such as diaphragm and condom with spermicide) or not surgically sterile (via hysterectomy, ovariectomy or bilateral tubal ligation) or not at least one year post menopausal; - Presence of any medically not controllable disease (e.g. uncontrolled arterial hypertension or diabetes mellitus); - Use of benzodiazepines, sedating antidepressants (mirtazapine or trazodone) or sedating antipsychotics (olanzapine and quetiapine) in the previous four weeks; - Severe cognitive disorders defined as a score < 18 on the MOCA; - Participation in another investigative drug trial within 2 months; - Subjects who are unlikely to be compliant and attend scheduled clinic visits as required as determined by the Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Melatonin
Participants will receive melatonin 5 mg once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.
Other:
Placebo
Participants will receive placebo once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.

Locations

Country Name City State
United States The University of Texas Health Science Center at Houston Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston Huntington's Disease Society of America

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in sleep quality, as assessed by the Pittsburgh Sleep Quality Index (PSQI) The PSQI is a 9-question instrument used to measure the quality and patterns of sleep in adults.
Scoring of the answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. A global sum of "5"or greater indicates a "poor" sleeper.
Baseline, week 5, week 9
Secondary Improvement in sleep quality, as assessed by the Huntington's disease (HD) sleep questionnaire This questionnaire contained 45 questions that focused on different sleep-related issues such as duration, quality of sleep, abnormal nocturnal behavior and quality of life.
The questionnaire has a total score of 19 points, scores of (0 - 3) represent the 'normal' range whilst, scores of (4 - 6) reflect 'mild' and scores of 7 and above indicate a 'significant' sleep disturbance.
Baseline, week 5, week 9
Secondary Improvement in daytime somnolence, as evaluated by the Epworth Sleepiness Scale (ESS) The ESS is a questionnaire designed to measure the subject's general level of daytime sleepiness.
This scale scores from 0-24, with higher scores showing severe excessive daytime sleepiness.
Baseline, week 5, week 9
Secondary Improvement in self-perceived cognitive function, as assessed by the Quality of Life in Neurological Disorders questionnaire (NeuroQOLv2.0) Cognition Function - Short Form It is an 8-question instrument designed and validated to evaluate perceived difficulties in cognitive abilities (e.g., memory, attention, and decision making, or in the application of such abilities to everyday tasks (e.g., planning, organizing, calculating, remembering and learning).
The score ranges from 0-100, with higher scores meaning a better or worse outcome according to the domain evaluated.
Baseline, week 5, week 9
Secondary Improvement in global cognitive functioning, as assessed by the Montreal cognitive assessment (MoCA) The MoCA was designed as a rapid screening instrument for mild cognitive dysfunction.
Scores on the MoCA range from zero to 30, with a score of 26 and higher generally considered normal.
Baseline, week 5, week 9
Secondary Improvement in quality of life, as evaluated by the Huntington's Disease Quality of Life Questionnaire (HDQoL) It is a disease-specific scale containing 40 questions, with answers including different types of frequency from "never" to "all of the time". Baseline, week 5, week 9
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Not yet recruiting NCT04429230 - Non-invasive Brain Stimulation in Huntington's Disease N/A
Recruiting NCT05032196 - Study of WVE-003 in Patients With Huntington's Disease Phase 1/Phase 2
Recruiting NCT03599076 - Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
Terminated NCT04617860 - Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease Phase 1/Phase 2
Completed NCT05748288 - Development of the Virtual Unified Huntington's Disease Rating Scale
Not yet recruiting NCT05360082 - Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
Not yet recruiting NCT04370470 - Development of Assessments for Later Stage HD
Recruiting NCT01834053 - Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea. Phase 1/Phase 2
Completed NCT01357681 - Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) Phase 2
Completed NCT01458470 - A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease Phase 2
Completed NCT00980694 - Bioavailability of Ubiquinol in Huntington Disease Phase 1
Completed NCT00146211 - TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease Phase 3
Recruiting NCT01412125 - Study of Biomarkers That Predict the Evolution of Huntington's Disease N/A
Completed NCT00075140 - Family Health After Predictive Huntington Disease (HD) Testing Phase 3
Recruiting NCT04818060 - Preparing for Prevention of Huntington's Disease (PREVENT-HD)
Active, not recruiting NCT04698551 - NIPD on cffDNA for Triplet Repeat Diseases
Not yet recruiting NCT04301726 - Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD Phase 1
Completed NCT03421327 - Genetic Risk: Whether, When, and How to Tell Adolescents
Recruiting NCT03296176 - Metabolomic Study in Huntington's Disease (METABO-HD) N/A